Table 2.

Estimated Survival Rates According to Recurrence Score and Assigned Treatment in the Intention-to-Treat Population.^*

End Point and Treatment Group	Rate at 5 Yr	Rate at 9 Yr
	percent
Invasive disease-free survival-†-
Score of ≤10, endocrine therapy	94.0±0.6	84.0±1.3
Score of 11–25, endocrine therapy	92.8±0.5	83.3 ±0.9
Score of 11–25, chemoendocrine therapy	93.1±0.5	84.3±0.8
Score of ≥26, chemoendocrine therapy	87.6±1.0	75.7±2.2
Freedom from recurrence of breast cancer at a distant site
Score of ≤ lO, endocrine therapy	99.3±0.2	96.8±0.7
Score of 11–25, endocrine therapy	98.0±0.3	94.5±0.5
Score of 11–25, chemoendocrine therapy	98.2±0.2	95.0±0.5
Score of ≥ 26, chemoendocrine therapy	93.0±0.8	86.8±1.7
Freedom from recurrence of breast cancer at a distant or local-regional site
Score of ≤ 10, endocrine therapy	98.8±0.3	95.0±0.8
Score of 11–25, endocrine therapy	96.9±0.3	92.2±0.6
Score of 11–25, chemoendocrine therapy	97.0±0.3	92.9±0.6
Score of ≥ 26, chemoendocrine therapy	91.0±0.8	84.8±1.7
Overall survival
Score of ≤ lO, endocrine therapy	98.0±0.4	93.7±0.8
Score of 11–25, endocrine therapy	98.0±0.2	93.9±0.5
Score of 11–25, chemoendocrine therapy	98.1±0.2	93.8±0.5
Score of ≥ 26, chemoendocrine therapy	95.9±0.6	89.3±1.4

^*Plus–minus values are Kaplan–Meier estimates ±SE.

^†Invasive disease–free survival was defined as freedom from invasive disease recurrence, second primary cancer, or death.